drugset / Trial / NCT00203164

Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients

NCT00203164

Phase 3 Completed 254 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study to look at the effectiveness, tolerability, and safety of one dose of rasagiline in advanced Parkinson's disease (PD) patients who have been treated with Levodopa/Carbidopa therapy.

Timeline

Start
2002-05
Primary completion
2005-07
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasagiline Small molecule 1 mg Oral

Indications